Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY With the most people ever in history currently living with HIV, finding a cure remains a global priority. Non-human primates (NHPs) are a clinically relevant model for developing strategies for HIV cure. The safety and efficacy of therapeutic curative approaches in ART-suppressed SIV-infected NHP have provided the basis for several strategies currently in human clinical trials. While the current daily ART regimen has advanced preclinical SIV cure research, it has its drawbacks. In addition to the high costs for staffing and drug administration, daily ART injections require daily manipulation of the NHP and unintended immune activation and perturbation from the carrier molecule Kleptose. Long-acting ART offers a novel and promising therapeutic approach as an alternative to both treat and prevent HIV. However, the impact of LA-ART on the latent viral reservoir is unknown and may alter approaches to cure HIV. Here, we are proposing to use LA-ART therapeutically in SIV-infected rhesus macaques to achieve full viral suppression. In specific aim 1, we will determine the ability of a long-acting antiretroviral regimen to achieve durable viral suppression in SIVmac239-infected rhesus macaques and assess the impact on the latent viral reservoir. In aim 2, we will characterize the safety, tolerability, and pharmacokinetics of repeated dosing of long-acting ART regimen and evaluate its effects on anti-SIV immunity. The results generated here will be directly compared to previously published historical controls that received conventional daily ART. This work will provide a safe and viable alternative to current daily antiretroviral therapies and lay the foundation for the next generation of ART in non-human primates.
Grant Summary
Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $483K for university, nonprofit, healthcare org. Applications are due 2028-01-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $483K
2028-01-31
- 1Confirm your organization is eligible for Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques: Frequently Asked Questions
Who is eligible for the Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques?
Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques provide?
Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques provides up to $483K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques deadline?
Applications for Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques are due 2028-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques?
To apply for Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.